Drug intelligence / Profile preview

HT-101 + HT-102

Development stage: Unknown
Lead developer: HepaThera
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HT-101 + HT-102 is a combination therapy developed by HepaThera Biotech for the treatment of chronic hepatitis B (CHB), aiming for a functional cure. The regimen consists of HT-101, a GalNAc-conjugated small interfering RNA (siRNA) that targets the hepatitis B virus (HBV) S region to silence viral transcripts and reduce antigen production, and HT-102 (also known as BM012), a neutralizing antibody designed to clear circulating viral proteins like HBsAg. By combining intracellular viral suppression with extracellular protein clearance, the therapy seeks to restore the host's immune response against HBV. It is currently in Phase 2 clinical trials.

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on HT-101 + HT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-101 + HT-102.

Explore the full profile